Taro, which has been warding off a takeover bid by the Indian firm ever since their proposed $454 million merger deal was called off in 2008, warned the shareholders that if Sun was successful in its bid, then the Israeli firm may be facing the same fate as that of Caraco Pharmaceutical Labs.
Sun Pharma and Dr Reddy's top list in terms of those who face most class-action litigation
Not much is heard or read about Sun Pharma's media-shy owner.
